In the BioHarmony Drug Report Database

"Preview" Icon

Flutemetamol (18f)

Vizamyl (flutemetamol f 18) is a small molecule pharmaceutical. Flutemetamol f 18 was first approved as Vizamyl on 2013-10-25. It has been approved in Europe to treat alzheimer disease and radionuclide imaging. The pharmaceutical is active against amyloid-beta precursor protein. Vizamyl’s patents are valid until 2028-09-16 (FDA).

 

Trade Name

 

Vizamyl
 

Common Name

 

flutemetamol f 18
 

ChEMBL ID

 

CHEMBL2042122
 

Indication

 

alzheimer disease, radionuclide imaging
 

Drug Class

 

Image (chem structure or protein)

Flutemetamol (18f) structure rendering